GLP-1 receptor agonists combined with progestin therapy significantly reduce endometrial cancer risk in women with uterine hyperplasia, according to a JAMA Network Open study. A separate meta-analysis finds patients regain 60% of weight lost one year after stopping GLP-1 RAs, with weight regain plateauing at 75.3% of treatment loss.
Pfizer is running a Phase 1 open-label multiple-dose study of PF-08653944 in adults with overweight or obesity. The study will assess gastric emptying and safety, with an update filed on 20 April 2026.
Lilly said a Phase IIIb trial of ixekizumab plus tirzepatide in psoriasis and obesity or overweight beat ixekizumab alone on complete skin clearance plus at least 10% weight loss at 36 weeks.
A study in Ophthalmology found tirzepatide use was associated with lower 12-month risk of new or progressive diabetic retinopathy versus lifestyle intervention alone. The analysis included about 174,000 matched patients.
The FDA has approved icotrokinra, the first oral IL-23 therapy for moderate-to-severe plaque psoriasis. Meanwhile, real-world research shows IL-23 inhibitors produce site-specific responses in high-impact areas like scalp and nails, and combination therapy with ixekizumab and tirzepatide shows superior results for psoriasis patients with obesity.
The FDA is set to make decisions on four drug applications in April 2026, including Orca-T for hematological malignancies, orforglipron for obesity, sparsentan for kidney disease, and a doravirine/islatravir combination for HIV-1.
Eli Lilly's orforglipron demonstrated superior A1C reduction and weight loss compared to oral semaglutide in the ACHIEVE-3 trial, with regulatory submissions filed in over 40 countries and a potential US decision expected in Q2 2026.
Genentech announced positive Phase II results for petrelintide, showing up to 10.7% mean weight loss versus 1.7% placebo at week 42 in people with overweight and obesity, with placebo-like tolerability.
Genentech announced positive Phase II results for CT-388, a dual GLP-1/GIP receptor agonist, showing 22.5% placebo-adjusted weight loss at 48 weeks in people with obesity. The treatment was well-tolerated with low discontinuation rates.
Roche announced positive phase II results for obesity drug petrelintide showing 10.7% weight reduction, while the FDA set a December 18 decision date for breast cancer drug giredestrant.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07611201 |
The Effects of GLP-1 Receptor Agonists on Chemosensory Function and Ingestive Behavior |
COMPLETED | |
| NCT07607587 |
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events |
NOT_YET_RECRUITING | PHASE1 |
| NCT07605169 |
Long-term Health and Economic Effects of an Individualized Lifestyle Intervention (LI-PAD-Extended) |
RECRUITING | NA |
| NCT07605052 |
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight |
NOT_YET_RECRUITING | PHASE1 |
| NCT07601061 |
Simplifying Diet Tracking in a Digital Weight Loss Intervention |
NOT_YET_RECRUITING | NA |
| NCT07597018 |
A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity |
NOT_YET_RECRUITING | PHASE1 |
| NCT07595549 |
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity |
NOT_YET_RECRUITING | PHASE3 |
| NCT07589608 |
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight |
NOT_YET_RECRUITING | PHASE2 |
| NCT07587710 |
A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver Function |
NOT_YET_RECRUITING | PHASE1 |
| NCT07583667 |
Nutrition Intervention Among Ethnic Minority Children Aged 5-16 Years in Tra Vinh Province, Vietnam |
COMPLETED | NA |
